IndexBox forecasts a 5.8% CAGR for the global endoscopy devices market through 2035

Impact level

⚪ Background

What happened

A report published by IndexBox on October 8, 2026, forecasts a 5.8% compound annual growth rate for the global endoscope equipment market from 2026 to 2035, with the market index reaching 176 by 2035 (2025 = 100). Growth drivers include global aging, rising chronic disease prevalence, wider adoption of minimally invasive surgery, and the expansion of ambulatory surgery centers. Single-use endoscopes are gradually gaining share due to infection-control needs. Gastrointestinal endoscopes lead with about 35% of the market, followed by laparoscopes at about 25%, arthroscopes at 15%, urology endoscopes at 13%, and bronchoscopes at 12%. Major participants include Olympus, Fujifilm, Boston Scientific, Medtronic, and Karl Storz. The report does not disclose a specific market value, unit prices, or financial data for individual manufacturers. [1]

Involves:Endoscope equipment、Single-use endoscopes、Gastrointestinal endoscopes、Laparoscopes、Bronchoscopes

Seller impact

• InferenceThe report provides a directional growth trend rather than a market value. The 5.8% CAGR and index of 176 are forecasts from a single research firm. The report also notes that more cautious purchasing, along with price pressure from GPOs and payers, could constrain value growth in some segments; volume growth does not necessarily mean prices will rise. [1]
• InferenceThe structural shift is that single-use endoscopes are gaining share amid infection-control needs and pressure from reprocessing costs, reflecting a shift in product mix. However, the report does not provide single-use product penetration, price differences, or certification barriers, so this evidence alone cannot establish how accessible the market is for sellers. [1]

Evidence that would disprove the assessment

• Assessment 1：If comparable third-party industry reports or annual reports from major manufacturers later show that growth in this category is materially below 5.8%, or if price indicators decline, this assessment should be revised downward.
• Assessment 2：If verifiable data show that single-use endoscopes’ share has stagnated or fallen in favor of reusable products, this structural assessment would no longer hold.